Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.54 |
| ▸ | VDR | P11473 | 12/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | AR | P10275 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5153604 | 0.93 | VDR (0.55) | ESR1ESR2VDRHDAC3HDAC6 | |
| SCHEMBL1525718 | 0.89 | ESR1 (0.59) | ESR1ESR2VDRHDAC3HDAC6 | |
| SCHEMBL5156575 | 0.86 | VDR (0.49) | ESR1ESR2VDRHDAC3HDAC6 | |
| SCHEMBL1056430 | 0.86 | HDAC6 (0.48) | VDRHDAC3HDAC6AR | |
| SCHEMBL5155936 | 0.85 | VDR (0.54) | VDRHDAC3HDAC6AR | |
| SCHEMBL5156434 | 0.85 | VDR (0.48) | ESR1ESR2VDRHDAC3HDAC6 | |
| SCHEMBL5156192 | 0.83 | HDAC6 (0.56) | VDRHDAC3HDAC6AR | |
| SCHEMBL5154028 | 0.83 | VDR (0.46) | ESR1ESR2VDRHDAC3HDAC6 | |
| SCHEMBL3066239 | 0.82 | HDAC6 (0.50) | VDRHDAC3HDAC6AR | |
| SCHEMBL13203908 | 0.82 | HDAC6 (0.50) | VDRHDAC3HDAC6AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863298-B2 | Bridged ring structures as pharmaceutical agents | EXELIXIS, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1675812-B1 | BRIDGED RING STRUCTURES AS PHARMACEUTICAL AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070225377-A1 | Bridged Ring Structures as Pharmaceutical Agents | X-CEPTOR THERAPEUTICS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1675812-A2 | BRIDGED RING STRUCTURES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005037755-A2 | BRIDGED RING STRUCTURES AS PHARMACEUTICAL AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225377-A1 | Bridged Ring Structures as Pharmaceutical Agents | VDR, CYP24A1, CYP2R1 | ESR1 265/4885ESR2 199/4885VDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.